On March 2, Novo Nordisk A/S (NYSE:NVO) announced a €432 million (DKK 3.2 billion) investment in its Monksland facility in ...

BEIJING] China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even ...

Now, it’s worth noting Stock Advisor’s total average return is 959 % — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

The Obesity Society, Obesity Medicine Association, and the Obesity Action Coalition have published joint guidance incorporating patient input.

Guidance for 2026 operating expenses was narrowed to $100–110 million, from $105–115 million previously. R&D expense expectations shifted lower, while SG&A guidance increased slightly. The company ...

While deaths from diseases like flu, RSV and COVID-19 are well documented, no verified reporting covers Americans dying from ...

RIVKIN Aesthetics reports the rise of weight loss drugs like GLP-1 is reshaping aesthetics, with many new patients seeking ...

Jenny Harrington, CEO Gilman Hill Asset Management, and Karen Firestone, Executive Chairman Aureus Asset Management, join ...

The supply chain that ultimately connects patients with their medicines is winding and complex — and growing more consolidated. In recent years, lawmakers have targeted the tactics used by drug ...

Monthly costs for Ozempic and Wegovy will decrease to $675 in 2027, matching price adjustments scheduled for federal Medicare programs.

On March 4, Henry McVey, KKR’s Head of Global Macro and Asset Allocation, appeared in a CNBC Television interview to discuss ...

March 4 () - Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance use disorders ...